Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Tolerogenic Dendritic Cells Attenuate Experimental Autoimmune Antimyeloperoxidase Glomerulonephritis.

Odobasic D, Oudin V, Ito K, Gan PY, Kitching AR, Holdsworth SR.

J Am Soc Nephrol. 2019 Aug 23. pii: ASN.2019030236. doi: 10.1681/ASN.2019030236. [Epub ahead of print]

PMID:
31444274
2.

Biologicals targeting T helper cell subset differentiating cytokines are effective in the treatment of murine anti-myeloperoxidase glomerulonephritis.

Gan PY, Chan A, Ooi JD, Dick J, Nagai K, O'Sullivan KM, Oudin V, Shim R, Kitching AR, Holdsworth SR.

Kidney Int. 2019 May 27. pii: S0085-2538(19)30531-9. doi: 10.1016/j.kint.2019.05.012. [Epub ahead of print]

PMID:
31443998
3.

Apoptotic Cell-Induced, Antigen-Specific Immunoregulation to Treat Experimental Antimyeloperoxidase GN.

Gan PY, Godfrey AS, Ooi JD, O'Sullivan KM, Oudin V, Kitching AR, Holdsworth SR.

J Am Soc Nephrol. 2019 Aug;30(8):1365-1374. doi: 10.1681/ASN.2018090955. Epub 2019 Jul 23.

PMID:
31337690
4.

OX40 ligand is inhibitory during the effector phase of crescentic glomerulonephritis.

Odobasic D, Ruth AJ, Oudin V, Kitching AR, Holdsworth SR.

Nephrol Dial Transplant. 2019 Mar 1;34(3):429-441. doi: 10.1093/ndt/gfy177.

PMID:
29939347

Supplemental Content

Support Center